<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02297854</url>
  </required_header>
  <id_info>
    <org_study_id>569-10</org_study_id>
    <nct_id>NCT02297854</nct_id>
  </id_info>
  <brief_title>Bioavailability Study of Valganciclovir Hydrochloride Tablets 450 mg Under Fasting Condition</brief_title>
  <official_title>Open Label, Balanced, Randomized, Two-treatment, Two-period, Two-sequence, Cross Over, Single Dose, Oral Bioequivalence Study of Valganciclovir Hydrochloride Tablets 450 mg Under Fasting Condition</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Dr. Reddy's Laboratories Limited</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Dr. Reddy's Laboratories Limited</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is to assess the Valganciclovir Hydrochloride Tablets 450 mg of Dr. Reddy's
      Laboratories Limited, India and Valcyte® (Valganciclovir HCl) tablets 450 mg of Genentech USA
      Inc., Group of Roche, South San Francisco in healthy, adult, human subjects under Fasting
      conditions.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Open label, balanced, randomized, two-treatment, two-period, two-sequence, cross over, single
      dose, oral bioequivalence study of Valganciclovir Hydrochloride Tablets 450 mg under Fasting
      conditions.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>July 2011</start_date>
  <completion_date type="Actual">August 2011</completion_date>
  <primary_completion_date type="Actual">July 2011</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Area under curve (AUC)</measure>
    <time_frame>0.00 and at 0.167, 0.333, 0.50, 0.667, 0.833, 1.00, 1.25, 1.50, 1.75, 2.00, 2.333, 2.667, 3.00, 3.333, 3.667, 4.00, 6.00, 8.00, 10.00, 12.00, 16.00 and 24.00 hours post dose</time_frame>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">83</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>Valganciclovir Hydrochloride Tablets 450 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Valganciclovir Hydrochloride Tablets 450 mg of Dr. Reddys Laboratories Limited</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Valcyte</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Valcyte® 450 mg tablets of Genentech USA Inc., San Francisco</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Valganciclovir Hydrochloride</intervention_name>
    <description>Valganciclovir Hydrochloride Tablets 450 mg</description>
    <arm_group_label>Valganciclovir Hydrochloride Tablets 450 mg</arm_group_label>
    <arm_group_label>Valcyte</arm_group_label>
    <other_name>Valcyte</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Healthy, adult, human volunteers between 18 to 55 years of age (both inclusive) living
             in and around Ahmedabad city or western part of India.

          -  Having a Body Mass Index (BMI) between 18.5-24.9 (both inclusive), calculated as
             weight in kg / height in meter2.

          -  Not having any significant disease in medical history or clinically significant
             abnormal findings during screening, medical history, physical examination, laboratory
             evaluations, 12- lead ECG and X-ray chest (postero-anterior view) recordings.

          -  Able to understand and comply with the study procedures, in the opinion of the
             principal investigator.

          -  Able to give voluntary written informed consent for participation in the trial.

        In case of Male subjects:

          -  Willing to practice an acceptable barrier contraception method of birth control for
             the entire duration of the study and at least for 90 days after the last dose
             administration, and in case of an accidental pregnancy of their spouse should be
             willing to abort the pregnancy. Or

          -  Surgically sterile who have undergone vasectomy.

        In case of female subjects:

          -  Surgically sterilized (Bilateral tubal ligation, bilateral oophorectomy, or
             hysterectomy) at least 6 months prior to study participation; Or

          -  If of child bearing potential is willing to use a suitable and effective double
             barrier contraceptive method or intra uterine device of birth control or abstinence
             for the entire during of the study and at least 90 days after the last study drug
             administration and in case of an accidental pregnancy should be willing to abort the
             pregnancy. Or

          -  Postmenopausal women: Women who are postmenopausal for at least 1 year having Follicle
             stimulating Hormone (FSH) level and serum estradiol level (without hormone replacement
             therapy) within specified limit suggestive of menopausal state, having normal
             bilateral mammogram and normal ultrasound abdomen and pelvis. And

          -  Pregnancy test must be negative. No female volunteers were enrolled in the trial.

        Exclusion Criteria :

        The exclusion criteria as per the protocol were as follows:

          -  Known hypersensitivity or idiosyncratic reaction to Valganciclovir and/or ganciclovir
             or any of the excipients or any related drug.

          -  History or presence of any disease or condition which might compromise the
             haemopoietic, renal, hepatic, endocrine, pulmonary, central nervous, cardiovascular,
             immunological, dermatological, gastrointestinal or any other body system.

          -  Ingestion of a medicine at any time within 14 days before dosing in Period I. In any
             such case subject selection will be at the discretion of the Principal Investigator.

          -  Any history or presence of asthma (including aspirin induced asthma) or nasal polyp or
             NSAID induced urticaria.

          -  A recent history of harmful use of alcohol(less than 2 years), i.e. alcohol
             consumption of more than 14 standard drinks per week for men and more than 7 standard
             drinks per week for women (A standard drink is defined as 360 ml of beer or 150 ml of
             wine or 45 ml of 40% distilled spirits, such as rum, whisky, brandy etc) or
             consumption of alcohol or alcoholic products within 48 hours prior to receiving study
             medicine.

          -  Smokers, who smoke 10 or more than 10 cigarettes / day or inability to abstain from
             smoking during the study

          -  The presence of clinically significant abnormal laboratory values during screening.

          -  Use of any recreational drugs or history of drug addiction or testing positive in
             prestudy drug scans.

          -  History or presence of psychiatric disorders.

          -  A history of difficulty in donating blood.

          -  Donation of blood (1 unit or 350 mL) or receipt of an investigational medicinal
             product or participation in a drug research study within a period of 90 days prior to
             the first dose of study medication. Elimination half-life of the study drug should be
             taken into consideration for inclusion of the subject in the study. Note: In case the
             blood loss is ≤ 200 mL; subject may be dosed 60 days after blood donation or last
             sample of the previous study.

          -  A positive hepatitis screen including hepatitis B surface antigen and HCV antibodies.

          -  A positive test result for HIV antibody.

          -  An unusual diet, for whatever reason (e.g. low-sodium), for four weeks prior to
             receiving the study medicine. In any such case subject selection will be at the
             discretion of the Principal Investigator.

          -  Consumption of grape fruit or grape fruit products within 48 hours prior to dosing.

          -  Nursing mothers (females). No female volunteers were enrolled in the trial.Nursing
             mothers (females).
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Dr. Aplesh kumar Patel, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Lambda Therapeutic Research Ltd</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Lambda Therapeutic Research Ltd</name>
      <address>
        <city>Ahmedabad</city>
        <state>Gujrat</state>
        <zip>380 061</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>India</country>
  </location_countries>
  <verification_date>September 2011</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 19, 2014</study_first_submitted>
  <study_first_submitted_qc>November 19, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 21, 2014</study_first_posted>
  <last_update_submitted>November 19, 2014</last_update_submitted>
  <last_update_submitted_qc>November 19, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 21, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Valganciclovir</mesh_term>
    <mesh_term>Ganciclovir</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

